Why better change communication matters for Talking Medicines’ workplace positioning

Tern plc

Talking Medicines is using a familiar workplace challenge to sharpen the case for its employee insight offering. In its latest commentary on change communication, the company focuses on a problem that remains highly relevant for employers: as organisations move through repeated rounds of transformation, the volume of internal messaging rises, but clarity does not always keep pace.

New technologies, changing work models and shifting business priorities are creating an environment in which employees are regularly asked to adapt. Against that backdrop, Talking Medicines argues that communication has become a critical management function, not simply an administrative task.

It places the company’s PeopleVoice proposition in a category linked to execution risk inside large organisations. If change programmes are poorly understood, businesses can face slower adoption, weaker engagement and reduced confidence among staff. By aligning its offer with that pressure point, Talking Medicines is presenting its technology as part of the infrastructure needed to support organisational change more effectively.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search